What were Orchid Pharma Ltd's latest quarterly results?
Orchid Pharma Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +9.1% (turning around (inflection up))
- Revenue Growth YoY: +0.4%
- Operating Margin: 11.0% (volatile)
Orchid Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +73.6%Weak4w Streak
In , Orchid Pharma Ltd (Pharma - API) is outperforming Nifty 500 with +73.6% relative strength. Fundamentals: Weak. On a 4-week streak.
Orchid Pharma Ltd Key Facts
- PE Ratio
- 180.0x
- Market Cap
- ₹4,886 Cr
- PAT Growth YoY
- +9%
- Revenue Growth YoY
- +0%
- OPM
- 11.0%
- RS vs Nifty 500
- +73.6%
PE: At PeakDanger Bubble
What's Happening
⚠️PE rising despite falling earnings — price running ahead of reality
💪Debt reduced 91% YoY — balance sheet strengthening
💰Trading 97% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+9%
Inflection Up
Revenue YoY
+0%
Inflection Up
Operating Margin
11.0%
-100 bps YoY
PE Ratio
180.0
Current Price
₹963
Fundamental Score
38/100
Weak
3Y PAT CAGR
-50%
Market Cap
4.9K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Orchid Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +0% | 0% | Inflection Up |
| PAT (Net Profit) | +9% | -50% | Inflection Up |
| OPM | 11.0% | -100 bps | Volatile |
Other Top Pharma - API Stocks Beating Nifty 500
Frequently Asked Questions: Orchid Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Orchid Pharma Ltd's profit growing or declining?
Orchid Pharma Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +9.1% (latest quarter)
- PAT Growth QoQ: +284.6% (sequential)
- 3-Year PAT CAGR: -50.0%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Orchid Pharma Ltd's revenue growth trend?
Orchid Pharma Ltd's revenue growth trend is turning around (inflection up).
- Revenue Growth YoY: +0.4%
- Revenue Growth QoQ: +15.0% (sequential)
- 3-Year Revenue CAGR: -0.5%
How is Orchid Pharma Ltd's operating margin trending?
Orchid Pharma Ltd's operating margin is volatile.
- Current OPM: 11.0%
- OPM Change YoY: -1.0% basis points
- OPM Change QoQ: +10.0% basis points
What is Orchid Pharma Ltd's 3-year profit and revenue CAGR?
Orchid Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: -50.0%
- 3-Year Revenue CAGR: -0.5%
Is Orchid Pharma Ltd's growth accelerating or decelerating?
Orchid Pharma Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.
- YoY Acceleration: +89.1% bps
- Sequential Acceleration: +100.0% bps
What is Orchid Pharma Ltd's trailing twelve month (TTM) performance?
Orchid Pharma Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹20 Cr
- TTM PAT Growth: -79.8% YoY
- TTM Revenue: ₹812 Cr
- TTM Revenue Growth: -11.8% YoY
- TTM Operating Margin: 4.9%
Is Orchid Pharma Ltd overvalued or undervalued?
Orchid Pharma Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 180.0x
- Price-to-Book: 3.8x
What is Orchid Pharma Ltd's current PE ratio?
Orchid Pharma Ltd's current PE ratio is 180.0x.
- Current PE: 180.0x
- Market Cap: 4.9K Cr
How does Orchid Pharma Ltd's valuation compare to its history?
Orchid Pharma Ltd's current PE is 180.0x.
- Current PE: 180.0x
- Valuation Assessment: Significantly Overvalued
What is Orchid Pharma Ltd's price-to-book ratio?
Orchid Pharma Ltd's price-to-book ratio is 3.8x.
- Price-to-Book (P/B): 3.8x
- Book Value per Share: ₹254
- Current Price: ₹963
Is Orchid Pharma Ltd a fundamentally strong company?
Orchid Pharma Ltd is rated Weak with a fundamental score of 37.56/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +0.4% (10% weight)
- PAT Growth YoY: +9.1% (10% weight)
- PAT Growth QoQ: +284.6% (10% weight)
- Margins stable (10% weight)
Is Orchid Pharma Ltd debt free?
Orchid Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹363 Cr
What is Orchid Pharma Ltd's return on equity (ROE) and ROCE?
Orchid Pharma Ltd's return ratios over recent years
- FY2024: ROCE 9.0%
- FY2025: ROCE 8.0%
- FY2026: ROCE 3.0%
Is Orchid Pharma Ltd's cash flow positive?
Orchid Pharma Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹101 Cr
- Free Cash Flow (FCF): ₹-184 Cr
- CFO/PAT Ratio: 481% (strong cash conversion)
What is Orchid Pharma Ltd's dividend yield?
Orchid Pharma Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹963
Who holds Orchid Pharma Ltd shares — promoters, FII, DII?
Orchid Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 69.8%
- FII (Foreign): 0.9%
- DII (Domestic): 20.2%
- Public: 9.0%
Is promoter holding increasing or decreasing in Orchid Pharma Ltd?
Orchid Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 69.8% (Mar 2026)
- Previous Quarter: 69.8% (Dec 2025)
- Change: 0.00% (stable)
How long has Orchid Pharma Ltd been outperforming Nifty 500?
Orchid Pharma Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Orchid Pharma Ltd a new momentum entry or an established outperformer?
Orchid Pharma Ltd is an established outperformer with 4 weeks of consecutive Nifty 500 outperformance.
Is Orchid Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Orchid Pharma Ltd may be worth studying
- Earnings growing at +9.1% YoY
- Cash flow is positive — CFO ₹101 Cr
What is the investment thesis for Orchid Pharma Ltd?
Orchid Pharma Ltd investment thesis summary:
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Orchid Pharma Ltd?
Orchid Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: turning around (inflection up)
- Margin Trend: volatile
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.